Russell Investments Group
XERS icon

Russell Investments Group’s Xeris Biopharma Holdings XERS Stock Holding History

Russell Investments Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Buy
384,195
+19,409
+5% +$129K ﹤0.01% 1827
2025
Q4 		$2.86M Buy
364,786
+113,408
+45% +$893K ﹤0.01% 1666
2025
Q3 		$2.05M Buy
251,378
+128,189
+104% +$852K ﹤0.01% 1840
2025
Q2 		$575K Sell
123,189
-8,498
-6% -$38.9K ﹤0.01% 2281
2025
Q1 		$723K Buy
131,687
+113,713
+633% +$459K ﹤0.01% 2165
2024
Q4 		$60.9K Buy
17,974
+16,848
+1,496% +$54.2K ﹤0.01% 2781
2024
Q3 		$3.21K Buy
1,126
+729
+184% +$1.87K ﹤0.01% 3302
2024
Q2 		$893 Buy
397
+195
+97% +$393 ﹤0.01% 3443
2024
Q1 		$446 Buy
+202
New +$523 ﹤0.01% 3220
2023
Q4 		– Sell
-119
Closed -$221 – 3318
2023
Q3 		$221 Buy
+119
New +$273 ﹤0.01% 3485
2021
Q3 		– Sell
-77,815
Closed -$316K – 3232
2021
Q2 		$316K Hold
77,815
– – ﹤0.01% 2763
2021
Q1 		$350K Hold
77,815
– – ﹤0.01% 2661
2020
Q4 		$382K Hold
77,815
– – ﹤0.01% 2535
2020
Q3 		$461K Buy
+77,815
New +$311K ﹤0.01% 2430

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Russell Investments Group's XERS Position: Q1 2026 in Review

Russell Investments Group increased its Xeris Biopharma Holdings (XERS) stake by 5.3% in Q1 2026, buying an estimated $129K and bringing the position to 384,195 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Russell Investments Group first reported a position in XERS in Q3 2020 and has held it in 14 quarters since. The position peaked at $2.86M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Russell Investments Group held 384,195 shares of Xeris Biopharma Holdings worth $2.23M as of Q1 2026.
  • Russell Investments Group bought 19,409 Xeris Biopharma Holdings shares in Q1 2026, an estimated $129K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #1827 holding.
  • Russell Investments Group first reported a position in Xeris Biopharma Holdings in Q3 2020 and has held it in 14 quarters since.
  • Russell Investments Group's Xeris Biopharma Holdings position peaked at $2.86M in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.